China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 152 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), as of September 30, 2023. This represents a year-on-year growth rate of 29.9%, according to calculations by GenScript Biotech. The sales figures were provided by partner Janssen Biotech and are pending independent audit.
Commercialization and Global Market Presence
Carvykti is being commercialized in the United States, Europe, and other international markets by Janssen Biotech, a subsidiary of Johnson & Johnson. The therapy received its first major market approvals last year, beginning with the US in March, followed by the European Medicines Agency (EMA) approval in May, and additional approvals in Japan. It is indicated for heavily pre-treated patients with relapsed/refractory multiple myeloma (MM). Currently, the drug is awaiting its first regulatory decision in China.
Sales Growth and Future Prospects
As of June 30, 2023, Carvykti generated USD 117 million in sales, highlighting its strong market performance. The continued growth and expansion into new markets suggest a promising trajectory for both Legend Biotech and GenScript as they navigate the competitive landscape of CAR-T therapies.-Fineline Info & Tech
